Clinical Trials Logo

Cardiomyopathy, Hypertrophic clinical trials

View clinical trials related to Cardiomyopathy, Hypertrophic.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06434415 Active, not recruiting - Clinical trials for Hypertrophic Cardiomyopathy

Prognostic Value of Coronary Angiography-Derived Index of Microcirculatory Resistance in Hypertrophic Cardiomyopathy Patients

Start date: January 1, 2017
Phase:
Study type: Observational

Coronary microvascular dysfunction (CMD) is among pathophysiological states of significance in hypertrophic cardiomyopathy (HCM). The index of microcirculatory resistance (IMR) has been recognized as an indicator of CMD and considered of important prognostic value in various conditions. The angiography-derived index of microcirculatory resistance (angio-IMR) is a novel guidewire-free method to assess IMR and proved to have favourable correlation with it. This study was designed to assess prognostic impact of CMD in HCM patients, using angio-IMR as a novel non-invasive assessment tool.

NCT ID: NCT06372457 Active, not recruiting - Clinical trials for Hypertrophic Cardiomyopathy (HCM)

COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

COLLIGO-HCM
Start date: December 1, 2023
Phase:
Study type: Observational

COLLIGO-HCM is a global observational study that will conduct observational research of hypertrophic cardiomyopathy (HCM) treatment in real-world clinical practice.

NCT ID: NCT06211595 Active, not recruiting - Clinical trials for Obstructive Hypertrophic Cardiomyopathy

Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy

Start date: October 13, 2022
Phase: N/A
Study type: Interventional

This is a prospective, single-center, single-arm clinical study. All patients were diagnosed with obstructive hypertrophic cardiomyopathy, and only subjects who met the instrument indications of this study were treated. After signing an informed consent form, subjects are enrolled and treated with the DragonFire Transcatheter Myocardial Ablation System. All subjects receive clinical follow-up immediately after the procedure, before discharge, 30 days after the procedure, 6 months after the procedure, and 12 months after the procedure.

NCT ID: NCT06031519 Active, not recruiting - Arrhythmia Clinical Trials

Impact of Liwen Procedure in Obstructive Hypertrophic Cardiomyopathy on Arrhythmias

Start date: August 22, 2023
Phase:
Study type: Observational

The goal of this observational study is to learn about the occurrence of various arrhythmias ( tachyarrhythmia and bradyarrhythmia ) during or after Percutaneous Intramyocardial Septal Radiofrequency Ablation. The main questions it aims to answer are: - To investigate the occurrence of various arrhythmias ( tachyarrhythmia and bradyarrhythmia ) during procedure and its relationship with clinical characteristics and procedural parameters - To analyze the changes of 12-lead electrocardiogram and 24-hour dynamic electrocardiogram before and after Percutaneous Intramyocardial Septal Radiofrequency Ablation and their relationships with clinical characteristics and procedural parameters

NCT ID: NCT06003478 Active, not recruiting - Clinical trials for Hypertrophic Obstructive Cardiomyopathy

The Safety and Influencing Factors of Liwen Procedure in The Treatment of Hypertrophic Cardiomyopathy

Start date: July 21, 2023
Phase:
Study type: Observational

Liwen procedure is generally safe and effective in treating hypertrophic cardiomyopathy, but a small proportion of patients have complications after the operation. The goal of this observational study is to explore the incidence of postoperative complications of the Liwen procedure in hypertrophic cardiomyopathy patients underwent Liwen procedure in Xijing Hospital. The main question it aims to answer are: - What is the incidence of complications in HCM patients underwent Liwen Procedure during postoperative hospitalization and a short-term follow-up period? - What is the relevant factors of complications in HCM patients who underwent Liwen Procedure during postoperative hospitalization and short-term follow-up period? Can the complications of surgical patients during postoperative hospitalization be predicted? Participants have been evaluated using a variety of medical examinations before they underwent Liwen Procedure. Variants collected from medical examination and case history were used to analyze the association with each postoperative complication.

NCT ID: NCT05582395 Active, not recruiting - Clinical trials for Cardiomyopathy, Hypertrophic

A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy

ODYSSEY-HCM
Start date: December 14, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).

NCT ID: NCT05556343 Active, not recruiting - Clinical trials for Cardiomyopathy, Hypertrophic

A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

MERCUTIO
Start date: January 18, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to characterize the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of MYK-224 in participants with obstructive Hypertrophic Cardiomyopathy (oHCM)

NCT ID: NCT05414175 Active, not recruiting - Clinical trials for Cardiomyopathy, Hypertrophic Obstructive

A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy

HORIZON-HCM
Start date: August 19, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effectiveness, safety, and tolerability of a 30-week course of mavacamten and the long-term effects of mavacamten in Japanese participants with symptomatic obstructive hypertrophic cardiomyopathy (HCM).

NCT ID: NCT05174416 Active, not recruiting - Clinical trials for Obstructive Hypertrophic Cardiomyopathy

A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM

Start date: January 4, 2022
Phase: Phase 3
Study type: Interventional

Mavacamtenis a novel, small molecule, selective allosteric inhibitor of cardiac-specific myosin, for the treatment of patients with symptomatic oHCM. This study will assess the efficacy and safety of mavacamten in Chinese adults with symptomatic oHCM.

NCT ID: NCT04943991 Active, not recruiting - Fabry Disease Clinical Trials

Fabry Disease in High-risk Patients With Left Ventricular Hypertrophy: Prevalence and Implementation of a Clinical Score

FAPREV-HCM
Start date: July 1, 2021
Phase: N/A
Study type: Interventional

This study aims to evaluate the prevalence of Fabry Disease (FD) among a cohort of high risk patients with left ventricular hypertrophy (LVH) presenting at the University Hospital Würzburg over the last 20 years. Fabry disease is a rare disease that is known to be consistently underdiagnosed due to its largely variable symptoms. Considering that an early Fabry diagnosis is crucial for maximum benefit from therapies available, screening for Fabry patients can contribute to preventing development and worsening of symptoms in Fabry patients with LVH. In addition, a positive diagnosis in a family member opens the possibility to diagnose further family members in an earlier stage of the disease, therefore allowing treatment of symptoms and organ manifestations before they become irreversible.